Sign in

CIK 0001689375

  • Accelerated filer
  • Smaller reporting company
  • Emerging growth company

Entrada Therapeutics, Inc.

Sign in to watch
Ticker
TRDA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813983399
Phone
+1 857-305-1825
Business address
ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
Former names
CycloPorters, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Planned sale CEO sold 1,000 shares at $16.17 ($16,174)
  8. 4 Option exercise Director acquired 11,918 shares (option exercise)
  9. 4 Planned sale Chief Scientific Officer sold 18,980 shares at an average $15.16 ($287,695)
  10. 4 Planned sale CEO sold 3,000 shares at an average $15.04 ($45,129)
  11. 4 Open-market buy Director bought 25,000 shares at $14.59 ($364,673)
  12. 4 Open-market buy Director bought 4,476 shares at an average $14.14 ($63,306)
  13. 4 Open-market buy Director bought 2,600 shares at $13.57 ($35,290)
  14. 4 Open-market buy Director bought 1,512 shares at $13.75 ($20,794)
  15. 4 Open-market buy Director bought 9,048 shares at an average $13.58 ($122,882)
  16. 4 Open-market buy Director bought 2,732 shares at an average $12.81 ($34,996)
  17. 4 Option exercise Chief Financial Officer acquired 9,000 shares (option exercise)
  18. 4 Planned sale Chief Financial Officer sold 4,086 shares at $12.31 ($50,285)
  19. 4 Planned sale President & COO sold 1,826 shares at $12.32 ($22,499)
  20. 4 Shares withheld for taxes CEO gave up 7,604 shares (to pay taxes)

Page 5 of 13 · 242 filings